Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) was the target of some unusual options trading on Friday. Stock traders bought 2,902 call options on the company. This is an increase of 92% compared to the average daily volume of 1,511 call options.
Alphatec Trading Up 2.0 %
ATEC traded up $0.19 on Friday, hitting $9.46. 466,159 shares of the company were exchanged, compared to its average volume of 1,975,557. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec has a 12 month low of $4.88 and a 12 month high of $14.88. The firm has a fifty day simple moving average of $10.95 and a two-hundred day simple moving average of $8.70. The stock has a market capitalization of $1.36 billion, a PE ratio of -7.38 and a beta of 1.39.
Alphatec (NASDAQ:ATEC – Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. Sell-side analysts expect that Alphatec will post -1.08 earnings per share for the current year.
Analysts Set New Price Targets
Check Out Our Latest Report on Alphatec
Insider Activity at Alphatec
In other Alphatec news, COO Scott Lish sold 27,453 shares of the stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the sale, the chief operating officer now owns 867,677 shares in the company, valued at approximately $9,969,608.73. This trade represents a 3.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Patrick Miles sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total value of $601,500.00. Following the completion of the transaction, the chief executive officer now owns 6,152,544 shares in the company, valued at $74,015,104.32. The trade was a 0.81 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 337,321 shares of company stock valued at $3,828,060. 22.80% of the stock is owned by insiders.
Hedge Funds Weigh In On Alphatec
Hedge funds and other institutional investors have recently modified their holdings of the stock. PharVision Advisers LLC bought a new position in shares of Alphatec in the 4th quarter worth approximately $201,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Alphatec by 11.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 224,643 shares of the medical technology company’s stock worth $2,062,000 after buying an additional 22,971 shares during the period. Western Standard LLC bought a new position in Alphatec in the 4th quarter valued at approximately $6,668,000. Soviero Asset Management LP bought a new position in Alphatec during the 4th quarter valued at about $918,000. Finally, Wexford Capital LP purchased a new stake in Alphatec during the 4th quarter valued at $95,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.
About Alphatec
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Featured Stories
- Five stocks we like better than Alphatec
- How to Use the MarketBeat Dividend Calculator
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
- What is the Australian Securities Exchange (ASX)
- SentinelOne Insider Selling? Why Investors Should Stay Bullish
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Market Momentum Shifts, But These 3 Stocks Are Built to Last
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.